Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) (REVEH)
Primary Purpose
Hematologic Neoplasms
Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Virtual Reality
Kalinox
Sponsored by
About this trial
This is an interventional other trial for Hematologic Neoplasms focused on measuring Therapeutic Virtual Reality, Pain related medical procedure management, Anxiety management, Osteo-medullary biopsy
Eligibility Criteria
Inclusion Criteria:
- Patient with malignant haematological pathology
- Patient who must have an osteo-medullary biopsy for diagnostic purposes
- Age ≥ 18 years
- Performance Status < 3
- Patient with no pelvic bone pain before inclusion
- Patient with normal coagulation balance (TP, Activated Partial Thromboplastin Time, fibrin) and platelet count> 50 G / L
- Patient affiliated to the social security scheme
- Patient giving written consent before any specific procedure related to the study
Exclusion Criteria:
- Patient regularly taking antalgic treatments from stage 2 or 3
- Patient with congenital coagulation disorder or acquired or taking anticoagulant therapy such as: fluindione, acenocoumarol, warfarin, dabigatran, apixaban or rivaroxaban
- Contraindication to a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen administration: true allergy, severe respiratory failure requiring continuous oxygen therapy, emphysema, pneumothorax, history of air embolism or diving accident, epilepsy or uncontrolled neurological disorder, unsubstituted vitamin deficiency B12 and folic acid, abdominal gas distension
- Any contraindication to the use of the headset: pacemaker or other implanted medical device
- Pregnancy or breastfeeding
- Persons deprived of liberty, under guardianship or under guardianship
- Dementia, mental impairment or psychiatric condition that may compromise patient informed consent and / or protocol compliance and follow-up of the trial
- Patient unable to undergo protocol monitoring for psychological, social, family or geographical reasons
Sites / Locations
- SOL Clinique Sainte-Anne
- Institut Bergonié
- HIA Bégin
- CHU Angers
- Centre Jean Bernard - Clinique Victor Hugo
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Kalinox®
Virtual Reality
Arm Description
The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen (Kalinox®)
The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a virtual reality (VR) session.
Outcomes
Primary Outcome Measures
Assessment of pain
Pain will be evaluated by Visual Analog Scale (0 = no pain at 10 = worst possible pain).
Secondary Outcome Measures
Assessment of tolerance
Quotation of nausea, dizziness or headache according to CTCAE
Assessment of the anxiety by specific questionnaire
Anxiety will be evaluated by Inventory of situational anxiety and anxiety trait (IASTA scale)
Assessment of the anxiety by blood pressure measurement
Anxiety will be evaluated by bood pressure measurement
Assessment of the fear of pain by questionnaire
Fear of pain will be evaluated by a specific questionnaire
Assessment of the fear of pain by Visual Analog Scale
Fear of pain will be evaluated by a Visual Analog Scale (0 = no pain at 10 = worst possible pain).
Assessment of residual pain
Pain will be evaluated by Visual Analog Scale (0 = no pain at 10 = worst possible pain).
Assessment of investigator's satisfaction
Satisfaction will be evaluated by a questionnaire for investigators
Assessment of patient's satisfaction
Satisfaction will be evaluated by a questionnaire for patients
Assessment of nurse's satisfaction
Satisfaction will be evaluated by a questionnaire for nurses
Assessment of drug consumption related to the osteo-medullary biopsy (Xylocaine)
Drug consumption related to medical procedure will be evaluated by the number of bottle of xylocaine® (bottle of 20 mL, concentration of 10mg/mL) used
Assessment of drug consumption related to the osteo-medullary biopsy (Kalinox)
Drug consumption related to medical procedure will be evaluated by the duration of exposure of a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen (time in minutes)
Full Information
NCT ID
NCT03483194
First Posted
March 15, 2018
Last Updated
June 22, 2020
Sponsor
Weprom
Collaborators
L'effet Papillon
1. Study Identification
Unique Protocol Identification Number
NCT03483194
Brief Title
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
Acronym
REVEH
Official Title
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care
Study Type
Interventional
2. Study Status
Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
September 6, 2018 (Actual)
Primary Completion Date
April 20, 2020 (Actual)
Study Completion Date
June 19, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Weprom
Collaborators
L'effet Papillon
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The management of hematological malignancies justifies the completion of a complete assessment before the start of treatment. This assessment includes imaging tests (computed tomography, position emission tomography, cavitary scintigraphy), biology and very often an exploration of the bone marrow by anterior or posterior iliac biopsy. Pains related to the disease (node compression, invasion of solid organs) are taken care of at the diagnosis and often relieved by the start of the specific treatment.
However, pain related to medical procedure is often overlooked and can lead to psychological trauma in some patients who may refuse to repeat these essential actions to assess the response to treatment.
Anxiety contributes to pain and various relaxation techniques have already proven their effectiveness. The goal of the protocol is to reduce the pain and anxiety associated with medical procedure by using virtual reality with a helmet proposed at the time of the gesture.
Detailed Description
Today, one third of the population suffers from anxiety and 20% of French people suffer from chronic pain. Many health situations or pathologies lead to difficult or painful care. The impact of drug solutions to relieve patients is often limited and more and more scientific studies are demonstrating the benefits of virtual reality to reduce pain, anxiety and addictions.
In 2011, following an experience of close to patient, a person created "l'Effet Papillon", a social enterprise that aims to create a concrete social impact in the lives of people with cancer, in situations of fragility or isolation and those who accompany them. Since 2011 the social enterprise has supported nearly 3,000 patients and today, the Butterfly Effect is a real partner of health actors by adopting a holistic approach to wellness in the face of disease and fragility.
Taking full advantage of the benefits of virtual reality that, used in medical settings, can reduce pain and anxiety, Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or or stress.
Bliss has been developed for and with patients in partnership with physicians, researchers and experts in virtual reality for therapeutic purposes.
Bliss offer a new tool for relaxation and well-being that relaxes and distracts users from moments of stress or anxiety.
The management of hematological malignancies justifies the completion of a complete assessment before the start of treatment. This assessment includes imaging tests (computed tomography, position emission tomography, cavitary scintigraphy), biology and very often an exploration of the bone marrow by anterior or posterior iliac biopsy. Pains related to the disease (node compression, invasion of solid organs) are taken care of at the diagnosis and often relieved by the start of the specific treatment.
However, pain related to medical procedure is often overlooked and can lead to psychological trauma in some patients who may refuse to repeat these essential actions to assess the response to treatment. Anxiety contributes to pain and various relaxation techniques have already proven their effectiveness.
During the osteo-medullary biopsy the patient will lie on his stomach with his hands positioned under the head. This position is the one recommended by the French Society of Hematology for an osteo-medullary biopsy.
The osteo-medullary biopsy remains independent of the object of the study and will be carried out according to the national recommendations.
For patients randomized to the "Standard" arm, the treatment will be the same as that proposed outside the study (a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen + 1 bottle of xylocaine® 20 mL at the concentration of 10 mg / mL).
For randomized patients in the "Virtual Reality" arm, the VR session should begin 5 minutes before the start of the procedure (+ 1 bottle of Xylocaine® 20 mL at a concentration of 10 mg / mL). The VR session will last between 15 and 30 minutes depending on the speed programmed. The patient can continue the session if the gesture ends before the end of the virtual reality program.
The goal of the protocol is to reduce the pain and anxiety associated with medical procedure by using virtual reality with a helmet proposed at the time of the gesture.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hematologic Neoplasms
Keywords
Therapeutic Virtual Reality, Pain related medical procedure management, Anxiety management, Osteo-medullary biopsy
7. Study Design
Primary Purpose
Other
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
126 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Kalinox®
Arm Type
Active Comparator
Arm Description
The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen (Kalinox®)
Arm Title
Virtual Reality
Arm Type
Experimental
Arm Description
The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a virtual reality (VR) session.
Intervention Type
Device
Intervention Name(s)
Virtual Reality
Other Intervention Name(s)
Bliss
Intervention Description
Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy
Intervention Type
Drug
Intervention Name(s)
Kalinox
Other Intervention Name(s)
Control
Intervention Description
Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
Primary Outcome Measure Information:
Title
Assessment of pain
Description
Pain will be evaluated by Visual Analog Scale (0 = no pain at 10 = worst possible pain).
Time Frame
Fifteen minutes after the osteo-medullary biopsy
Secondary Outcome Measure Information:
Title
Assessment of tolerance
Description
Quotation of nausea, dizziness or headache according to CTCAE
Time Frame
During or within fifteen minutes after the osteo-medullary biopsy
Title
Assessment of the anxiety by specific questionnaire
Description
Anxiety will be evaluated by Inventory of situational anxiety and anxiety trait (IASTA scale)
Time Frame
Fifteen minutes after the osteo-medullary biopsy
Title
Assessment of the anxiety by blood pressure measurement
Description
Anxiety will be evaluated by bood pressure measurement
Time Frame
Fifteen minutes after the osteo-medullary biopsy
Title
Assessment of the fear of pain by questionnaire
Description
Fear of pain will be evaluated by a specific questionnaire
Time Frame
Assessment at Baseline
Title
Assessment of the fear of pain by Visual Analog Scale
Description
Fear of pain will be evaluated by a Visual Analog Scale (0 = no pain at 10 = worst possible pain).
Time Frame
Assessment at Baseline
Title
Assessment of residual pain
Description
Pain will be evaluated by Visual Analog Scale (0 = no pain at 10 = worst possible pain).
Time Frame
One month after the osteo-medullary biopsy
Title
Assessment of investigator's satisfaction
Description
Satisfaction will be evaluated by a questionnaire for investigators
Time Frame
Fifteen minutes after the osteo-medullary biopsy
Title
Assessment of patient's satisfaction
Description
Satisfaction will be evaluated by a questionnaire for patients
Time Frame
Fifteen minutes after the osteo-medullary biopsy
Title
Assessment of nurse's satisfaction
Description
Satisfaction will be evaluated by a questionnaire for nurses
Time Frame
Fifteen minutes after the osteo-medullary biopsy
Title
Assessment of drug consumption related to the osteo-medullary biopsy (Xylocaine)
Description
Drug consumption related to medical procedure will be evaluated by the number of bottle of xylocaine® (bottle of 20 mL, concentration of 10mg/mL) used
Time Frame
During the osteo-medullary biopsy
Title
Assessment of drug consumption related to the osteo-medullary biopsy (Kalinox)
Description
Drug consumption related to medical procedure will be evaluated by the duration of exposure of a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen (time in minutes)
Time Frame
During the osteo-medullary biopsy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with malignant haematological pathology
Patient who must have an osteo-medullary biopsy for diagnostic purposes
Age ≥ 18 years
Performance Status < 3
Patient with no pelvic bone pain before inclusion
Patient with normal coagulation balance (TP, Activated Partial Thromboplastin Time, fibrin) and platelet count> 50 G / L
Patient affiliated to the social security scheme
Patient giving written consent before any specific procedure related to the study
Exclusion Criteria:
Patient regularly taking antalgic treatments from stage 2 or 3
Patient with congenital coagulation disorder or acquired or taking anticoagulant therapy such as: fluindione, acenocoumarol, warfarin, dabigatran, apixaban or rivaroxaban
Contraindication to a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen administration: true allergy, severe respiratory failure requiring continuous oxygen therapy, emphysema, pneumothorax, history of air embolism or diving accident, epilepsy or uncontrolled neurological disorder, unsubstituted vitamin deficiency B12 and folic acid, abdominal gas distension
Any contraindication to the use of the headset: pacemaker or other implanted medical device
Pregnancy or breastfeeding
Persons deprived of liberty, under guardianship or under guardianship
Dementia, mental impairment or psychiatric condition that may compromise patient informed consent and / or protocol compliance and follow-up of the trial
Patient unable to undergo protocol monitoring for psychological, social, family or geographical reasons
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Katell LE DU, MD
Organizational Affiliation
Centre Jean Bernard - Le Mans
Official's Role
Principal Investigator
Facility Information:
Facility Name
SOL Clinique Sainte-Anne
City
Strasbourg
State/Province
Alsace
ZIP/Postal Code
67000
Country
France
Facility Name
Institut Bergonié
City
Bordeaux
State/Province
Gironde
ZIP/Postal Code
33000
Country
France
Facility Name
HIA Bégin
City
Saint-Mandé
State/Province
Ile De France
ZIP/Postal Code
94160
Country
France
Facility Name
CHU Angers
City
Angers
State/Province
Pays De Loire
ZIP/Postal Code
49933
Country
France
Facility Name
Centre Jean Bernard - Clinique Victor Hugo
City
Le Mans
ZIP/Postal Code
72000
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
We'll reach out to this number within 24 hrs